New recommendations for the quality and safety of tissues and cells for clinical application and its significance for the practice of tissue establishments performing cryopreservation
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F21%3A10438980" target="_blank" >RIV/00179906:_____/21:10438980 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00216208:11150/21:10438980
Výsledek na webu
<a href="https://doi.org/10.18462/iir.cryo.2021.0038" target="_blank" >https://doi.org/10.18462/iir.cryo.2021.0038</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.18462/iir.cryo.2021.0038" target="_blank" >10.18462/iir.cryo.2021.0038</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
New recommendations for the quality and safety of tissues and cells for clinical application and its significance for the practice of tissue establishments performing cryopreservation
Popis výsledku v původním jazyce
The processes of procurement, processing, storage and distribution of cells and tissues of human origin used for clinical application are regulated in the European Union member states by the Directive of the European Parliament and Council No.2004/23/EC harmonized in the Czech Republic by the Act No.296/2008 Coll. and the Decree of the Ministry of Health No. 422/2008 Coll. In the Evaluation report from 2019 dealing with fulfilling of requirements of the above mentioned Directive in individual member states, the European Commission pointed out the significance of the document: "Guide to the Quality and Safety of Tissues and Cells for Human Application", the 4th Edition, issued by the European Directorate for the Quality of Medicines in 2019. This document includes specifications of cryopreserved haematopoietic progenitor cells derived from bone marrow, peripheral blood and cord blood as well as of non-mobilized peripheral blood mononuclear cells. The cryoprotectant dimethylsulphoxide (DMSO) is recommended to be used in concentrations 5 - 10 % (v/v) and in the daily dose not exceeding 1 g per kg of the patient's weight. DMSO removal before clinical administration is recommended to be performed in specific situations defined in the standard operating procedures of the tissue establishment. A guide defining Good Tissue Practice is a part of this document. The authors expect that the above cited document represents a basis for the planed upgrade of the Directive 2004/23/EC and of the Commission Directives 2006/17/EC and 2006/86/EC.
Název v anglickém jazyce
New recommendations for the quality and safety of tissues and cells for clinical application and its significance for the practice of tissue establishments performing cryopreservation
Popis výsledku anglicky
The processes of procurement, processing, storage and distribution of cells and tissues of human origin used for clinical application are regulated in the European Union member states by the Directive of the European Parliament and Council No.2004/23/EC harmonized in the Czech Republic by the Act No.296/2008 Coll. and the Decree of the Ministry of Health No. 422/2008 Coll. In the Evaluation report from 2019 dealing with fulfilling of requirements of the above mentioned Directive in individual member states, the European Commission pointed out the significance of the document: "Guide to the Quality and Safety of Tissues and Cells for Human Application", the 4th Edition, issued by the European Directorate for the Quality of Medicines in 2019. This document includes specifications of cryopreserved haematopoietic progenitor cells derived from bone marrow, peripheral blood and cord blood as well as of non-mobilized peripheral blood mononuclear cells. The cryoprotectant dimethylsulphoxide (DMSO) is recommended to be used in concentrations 5 - 10 % (v/v) and in the daily dose not exceeding 1 g per kg of the patient's weight. DMSO removal before clinical administration is recommended to be performed in specific situations defined in the standard operating procedures of the tissue establishment. A guide defining Good Tissue Practice is a part of this document. The authors expect that the above cited document represents a basis for the planed upgrade of the Directive 2004/23/EC and of the Commission Directives 2006/17/EC and 2006/86/EC.
Klasifikace
Druh
D - Stať ve sborníku
CEP obor
—
OECD FORD obor
30205 - Hematology
Návaznosti výsledku
Projekt
—
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2021
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název statě ve sborníku
Cryogenics 2021 online. The 16th Cryogenics 2021 IIR International Conference, October 5-7, 2021. Proceedings
ISBN
978-2-36215-047-0
ISSN
0151-1637
e-ISSN
—
Počet stran výsledku
6
Strana od-do
167-172
Název nakladatele
International Institute of Refrigeration
Místo vydání
Paris
Místo konání akce
Czech Republic
Datum konání akce
5. 10. 2021
Typ akce podle státní příslušnosti
WRD - Celosvětová akce
Kód UT WoS článku
001304907400021